Arcturus Therapeutics and the Cystic Fibrosis Foundation continue partnership to further the development of ARCT-032, an experimental mRNA therapy for Cystic Fibrosis.

Inozyme Pharma reports encouraging preliminary results from ongoing INZ-701 phase 1/2 studies in adults with ENPP1 and ABCC6 (PXE) deficiencies.

Omega Therapeutics, Inc. reported positive early findings from the first two doses of its Phase 1/2 MYCHELANGELO™ I study on OTX-2002. The study focuses on hepatocellular carcinoma patients and others with solid tumors linked to the c-MYC gene.

Immunovant, Inc. recently revealed preliminary results of a Phase 1 clinical trial for IMVT-1402.

Nippon Kayaku Co., Ltd. and Celltrion Healthcare Japan K.K. have gained approval to manufacture and sell various Adalimumab BS Subcutaneous Injections and Pens in Japan.

AcuraStem proclaimed it has signed a licensing deal with Takeda.

Alvotech revealed that its distribution associate in Japan, Fuji Pharma Co., Ltd., has obtained commercialisation authorization for AVT04 (ustekinumab).

TransCode Therapeutics has reported positive findings with its primary treatment candidate, TTX-MC138, in mouse models with human glioblastoma multiforme tumors.

NMD Pharma A/S has revealed that the initial patient has received their first dose in a Phase II clinical study of the ClC-1 inhibitor NMD670 in individuals affected by spinal muscular atrophy.

Sandoz gains consent from the European Commission for its unique multiple sclerosis biosimilar, Tyruko® (natalizumab) in Europe.

Lantern Pharma Inc. has started Phase 1 clinical trial on its experimental drug, LP-184, for advanced solid tumors. This is part of the company's ongoing clinical drug development.

Escient Pharmaceuticals commences trial-based study of EP262, an innovative, orally-taken MRGPRX2 blocker for chronic inducible hives.